Lantern Pharma Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Lantern Pharma Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Self-Funding Ratio: Over the last 3 years operating cash was negative while the company kept spending on investment (capex). Lower than almost all Healthcare companies in United States.
- Debt Due Cover Ratio: Operating cash was negative last year, while some debt falls due within a year. Lower than 92% of Healthcare companies in United States.
- Cash Cushion Ratio: Cash, after subtracting all debt, is 1.0 times its market value (net cash). Higher than 89% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
-1,447.7×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than almost all Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 1/3Sales grew in 0 of the last 3 years; profit grew in 1 of 3.
Less steady than 86% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-199.6×Operating cash was negative last year, while some debt falls due within a year.
Lower than 92% of Healthcare companies in United States.
Cash Cushion Ratio
1.0× cashCash, after subtracting all debt, is 1.0 times its market value (net cash).
Higher than 89% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (9)
Lantern Pharma Inc. made a loss over the last year. Lantern Pharma Inc. owes $1.37 for every $1 it owns. Lantern Pharma Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossLantern Pharma Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
-2.97Lantern Pharma Inc.'s book value is negative (it owes more than it owns), so P/B is not meaningful.
Market cap
$10 MThe total market value of all of Lantern Pharma Inc.'s shares at today's price (share price × number of shares), smaller than 88% of Healthcare companies in United States. PosiCap size class: Nano Cap.
Net worth (book value)
NegativeLantern Pharma Inc.'s net worth is negative ($3 M below zero, balance sheet 30 Jun 2026): it owes more than it owns, so book value per share and P/B are not meaningful.
Return on equity (ROE)
-400.9%Lantern Pharma Inc. lost 400.9% of its shareholders' money over the last year, lower than 92% of Healthcare companies in United States.
Owes vs Owns
1.37×Lantern Pharma Inc. owes $1.37 for every $1 it owns, so it owes more than it owns, higher than 93% of Healthcare companies in United States.
Dividend yield
NoneLantern Pharma Inc. does not currently pay a dividend.
Profit growth
LossLantern Pharma Inc. made a loss in each of the last two years.
Cash vs debt
Net cashLantern Pharma Inc. held $10 M more cash than debt (net cash) at Dec 2025.
Questions
What is Lantern Pharma Inc.'s return on equity?
Lantern Pharma Inc. lost 400.9% of its shareholders' money over the last year, lower than 92% of Healthcare companies in United States.
How much does Lantern Pharma Inc. owe compared with what it owns?
Lantern Pharma Inc. owes $1.37 for every $1 it owns, so it owes more than it owns, higher than 93% of Healthcare companies in United States.
Does Lantern Pharma Inc. pay a dividend?
No. Lantern Pharma Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.